All In Biotech

Drug Trial Radar · NCT02847429

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Crenolanib in Subjects With Advanced or Metastatic Gastrointestinal Stromal Tumors With a D842V Mutation in the PDGFRA Gene

Last checked: Nov 19, 2026Latest source record: Jan 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 2016

Primary completion

Aug 2021

Study completion Aug 2021

Sponsor

Lead sponsor
Arog Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
Centre Leon Berard; Fox Chase Cancer Center
First posted
Jul 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blinded, placebo-controlled, trial of oral crenolanib versus oral placebo in combination with best supportive care in subjects with advanced or metastatic GIST with a D842V mutation in the PDGFRA gene. Approximately 120 subjects will be randomized in a 2:1 ratio to receive either crenolanib 100 mg or matching placebo orally (PO) 3 times daily (TID) in combination with best supportive care.

Conditions

  • GIST With D842V Mutated PDGFRA Gene

Interventions

  • CrenolanibDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) will be measured from the date of randomization to the date of the first objective radiological disease progression according to centralized committee assessment using modified RECIST version 1.1 or death.Time frame: 3 years

Locations

23 sites in 7 countries. Site status is shown where the registry gives one.

  • Sarcoma Oncology Center

    Santa Monica, California

  • University of Miami

    Miami, Florida

  • Duke Cancer Institute

    Durham, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

  • Institut Bergonie

    Bordeaux, France

  • Centre Leon Berard

    Lyon, France

  • La Timone University Hospital

    Marseille, France

  • Centre Hospitalier Universitaire (CHU) de Reims

    Reims, France

  • HELIOS Klinikum Berlin-Buch

    Berlin, Germany

  • Mannheim University Medical Centre, University of Heidelberg

    Mannheim, Germany

  • Universitätsklinikum München

    Munich, Germany

  • Policlinico S. Orsola-Malpighi

    Bologna, Italy

  • Istituto Nazionale Tumori

    Milan, Italy

  • Institut Regina Elena / IFO

    Rome, Italy

  • Candiolo Cancer Institute - FPO, IRCCS

    Turin, Italy

  • University Hospital The Norwegian Radium Hospital

    Oslo, Norway

  • M Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology

    Warsaw, Poland

  • Vall d'Hebron University Hospital

    Barcelona, Spain

  • Hospital Universitario Puerta de Hierro

    Madrid, Spain

  • Hospital Virgen del Rocio

    Seville, Spain

  • Fundación Instituto Valenciano de Oncología

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.